3 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Behavior, Animal: new trials by email Literature Review of Behavior, Animal trials Research Report on Behavior, Animal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting Orforglipron - Diabetes Mellitus, Type 2, Diabetes Melletus | Phase 3 | Recruiting | Eli Lilly and Company | 130 | 2026-07-15 | 2026-10-08 |
| Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity Semaglutide 1.7mg subcutaneous, Placebo - Obesity/Therapy | Phase 3 | Not yet recruiting | University of Colorado, Denver | 120 | 2026-06-15 | 2026-07-02 |
| Suaahara Impact Evaluation: End-line Survey Health and family planning, Nutrition, Agriculture and homestead food production - Nutritional Stunting, Feeding Behavior | Phase 3 | Completed | University of South Carolina | 2480 | 2022-06-17 | 2023-01-06 |
| Behavioral Mechanism of Energy Compensation With Exercise exericse - Obesity, Weight Loss | Phase 3 | Completed | Kyle Flack | 32 | 2021-02-09 | 2023-01-04 |
| Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM Placebo, Bromocriptine-QR - Overweight and Obesity, Eating Behavior | Phase 3 | Completed | University of North Carolina, Chapel Hill | 55 | 2017-09-19 | 2022-09-07 |
| Feeding Education in Patients Submitted to Coronary Angioplasty Traditional, Behavioral - Coronary Angioplasty, Coronary Disease | Phase 3 | Unknown | University of Sao Paulo General Hospital | 200 | 2008-04-01 | 2009-12-11 |
Feeding Behavior (6) · Obesity (3) · Behavior (1) · Coronary Disease (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Fasting (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Motor Activity (1) · Nutritional and Metabolic Diseases (1) · Overweight (1) · Weight Loss (1)
Behavior (5) · Body Weight (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Overweight (2) · Body Weight Changes (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Heart Diseases (1) · Myocardial Ischemia (1) · Vascular Diseases (1)
Agriculture (1) · Bromocriptine (1) · Family Planning Services (1) · Health (1) · Hygiene (1) · Injections, Subcutaneous (1) · Nutritional Status (1) · Sanitation (1) · Water (1) · orforglipron (1) · semaglutide (1)
Eli Lilly and Company (1) · Kyle Flack (1) · University of Colorado, Denver (1) · University of North Carolina, Chapel Hill (1) · University of Sao Paulo General Hospital (1) · University of South Carolina (1)
United States (3) · Brazil (1) · India (1) · Nepal (1) · Saudi Arabia (1) · South Africa (1) · United Arab Emirates (1)
Allison Shapiro, PhD, MPH (1) · Edward A Frongillo, PhD (1) · Kyle S Burger, MPH, RD, PhD (1)
P30GM127211 (1)